Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, talks on identifying molecular or genetic features in tumor samples to help predict why some patients respond well to CDK4/6 inhibitors and others become resistant. At the San Antonio Breast Cancer Symposium (SABCS) 2022, data was presented investigating NF1 mutation as a potential marker of resistance to CDK4/6 inhibitors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.